Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 24,215 shares traded hands during mid-day trading, a decline of 16% from the previous session’s volume of 28,850 shares.The stock last traded at $8.86 and had previously closed at $8.04.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Friday, September 20th.
Get Our Latest Research Report on ALGS
Aligos Therapeutics Trading Down 0.5 %
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the business earned ($10.75) earnings per share. Research analysts expect that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current fiscal year.
Institutional Trading of Aligos Therapeutics
Several hedge funds have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in Aligos Therapeutics during the fourth quarter worth $4,538,000. Altitude Crest Partners Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth $1,889,000. Opaleye Management Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth $861,000. Finally, Acadian Asset Management LLC raised its holdings in Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
See Also
- Five stocks we like better than Aligos Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- Chinese Stock Surge: Should You Invest After Stimulus Boost?
- Business Services Stocks Investing
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Airline Stocks – Top Airline Stocks to Buy Now
- 2 Energy Stocks Fueling the AI Datacenter Boom
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.